
    
      This a Phase III, double-blind, placebo-controlled, multi-center study of intravenous OvaRexÂ®
      MAb-B43.13 as post-chemotherapy consolidation for epithelial carcinoma of ovarian, tubal, or
      peritoneal origin.
    
  